Lauren, according to your own attached link:

"Because Tysabri increases the risk of PML, it is generally recommended for patients who have had an inadequate response to, or cannot tolerate, any of the other disease-modifying therapies that are available for treating MS (see Precautions)."

Which is what I said, in effect, but just my own words:

Recommended = generally prescribed
Failed = inadequate response (or cannot tolerate)
SAFER = "because Tysabri increases the risk of PML"

So, according to your own data on the CRABs (which includes only the effect on relapse rates, not disease progression, BTW):

Avonex = 32%
Betaseron = 34%
Copaxone = 29%
Rebif = 32%

Based on that data, I still say that they have virtually equal efficacy, and the only notable difference is whether one of these 4 different drugs might work better for an idividual.

Bethany, I would still recommend you ask your Neuro "on what basis" he is recommending a switch to a (currently) much riskier drug, instead of trying you on one of the other existing drug options.

Cherie